Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly prescribed for the treatment of type 2 diabetes and obesity. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.